tiprankstipranks
Advertisement
Advertisement

ASND Stock Latest News

Ascendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge
Company AnnouncementsAscendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge
14d ago
6K
ASND
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
PremiumCompany Announcements
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
14d ago
6K
ASND
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
PremiumCompany Announcements
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
15d ago
6K
ASND
Ascendis Pharma announces commencement of trading of shares on Nasdaq
PremiumThe Fly
Ascendis Pharma announces commencement of trading of shares on Nasdaq
15d ago
ASND
Ascendis Tracks YORVIPATH in Breast Milk: What Investors Should Know
PremiumCompany Announcements
Ascendis Tracks YORVIPATH in Breast Milk: What Investors Should Know
17d ago
ASND
2 Best ETFs to Buy in April 2026, According to Analysts
PremiumMarket News2 Best ETFs to Buy in April 2026, According to Analysts
18d ago
LLY
ABBV
Ascendis Pharma price target raised to $292 from $262 at BofA
Premium
The Fly
Ascendis Pharma price target raised to $292 from $262 at BofA
19d ago
ASND
Ascendis Pharma Issues New Employee Warrants as Part of Long-Term Incentive Program
Premium
Company Announcements
Ascendis Pharma Issues New Employee Warrants as Part of Long-Term Incentive Program
19d ago
6K
ASND
Ascendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia
PremiumCompany Announcements
Ascendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia
27d ago
6K
ASND
Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq
PremiumCompany Announcements
Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq
27d ago
6K
ASND
Ascendis Pharma to list ordinary shares directly on Nasdaq
PremiumThe Fly
Ascendis Pharma to list ordinary shares directly on Nasdaq
27d ago
ASND
Ascendis Pharma announces new data from COACH trial
PremiumThe Fly
Ascendis Pharma announces new data from COACH trial
27d ago
ASND
Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia
PremiumCompany AnnouncementsAscendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia
28d ago
6K
ASND
Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.
Premium
The Fly
Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.
29d ago
ASND
Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises
Premium
Company Announcements
Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises
1M ago
6K
ASND
Ascendis Pharma Shareholders Back Board, Loss Carryforward and New Buyback Mandate at 2026 AGM
PremiumCompany Announcements
Ascendis Pharma Shareholders Back Board, Loss Carryforward and New Buyback Mandate at 2026 AGM
1M ago
6K
ASND
Ascendis Pharma Posts Positive Phase 2 Results for Once-Weekly TransCon hGH in Turner Syndrome
PremiumCompany Announcements
Ascendis Pharma Posts Positive Phase 2 Results for Once-Weekly TransCon hGH in Turner Syndrome
2M ago
6K
ASND
Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome
PremiumThe Fly
Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome
2M ago
ASND
Ascendis Pharma Reports Two-Year Data Showing Sustained Benefits of YUVIWEL in Children With Achondroplasia
PremiumCompany Announcements
Ascendis Pharma Reports Two-Year Data Showing Sustained Benefits of YUVIWEL in Children With Achondroplasia
2M ago
6K
ASND
Ascendis Pharma assumed with a Buy at Jefferies
PremiumThe FlyAscendis Pharma assumed with a Buy at Jefferies
2M ago
ASND
Ascendis Pharma announces new data from Navepegritide trial
Premium
The Fly
Ascendis Pharma announces new data from Navepegritide trial
2M ago
ASND
Ascendis Pharma: Durable Endocrine Franchise Growth and Emerging Pipeline Upside Support Buy Rating
Premium
Ratings
Ascendis Pharma: Durable Endocrine Franchise Growth and Emerging Pipeline Upside Support Buy Rating
2M ago
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >